Evaluation of Association Between Oral and Topical Terbinafine Use in Pregnancy and Risk of Major Malformations and Spontaneous Abortion

Analyses of cohort [1,650,649 pregnancies (oral terbinafine-exposed;n = 891; topical terbinafine-exposed;n = 3174, matched to 40,650 unexposed pregnancies) found no increased risk of major malformations/spontaneous abortion among pregnancies exposed to oral or topical terbinafine

SPS commentary:

According to an editorial, this study makes a substantial contribution to the nearly absent literature on the use of terbinafine during pregnancy, and suggests that among the antifungal medications, it is possible terbinafine is the safest one currently available for use in pregnancy, particularly of the oral formulations. However it cautions that it is important to acknowledge the uncertainty in this field and question the appropriateness of treating non–life-threatening diseases during pregnancy and lactation.

JAMA Dermatology

Resource links:

Editorial